"More on Eculizumab for Congenital Atypical Hemolytic-Uremic Syndrome", NEW ENGLAND JOURNAL OF MEDICINE, vol. 360, no. 20, 14 May 2009 (2009-05-14), pages 2142 - 2143, XP055186122, ISSN: 0028-4793, DOI: 10.1056/NEJMc090453 (B1)

US-A1- 2005 191 298 (B1)

ANONYMOUS: "Assessment report Soliris eculizumab Procedure No.: EMEA/H/C/000791/II/0027", 22 SEPTEMBER 2011 EXT/834951/2011 CORR1 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP), 1 January 2015 (2015-01-01), pages 5555, XP055493808, Retrieved from the Internet <URL:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000791/WC500119185.pdf> [retrieved on 20180719] (B1)

ANONYMOUS: "Atypical hemolytic uremic syndrome - Wikipedia", WIKIPEDIA, 20 December 2016 (2016-12-20), XP055330648, Retrieved from the Internet <URL:https://en.wikipedia.org/wiki/Atypical_hemolytic_uremic_syndrome> [retrieved on 20161220] (B1)

CHANTAL LOIRAT ET AL: "Complement and the atypical hemolytic uremic syndrome in children", PEDIATRIC NEPHROLOGY ; JOURNAL OF THE INTERNATIONAL PEDIATRIC NEPHROLOGY ASSOCIATION, SPRINGER, BERLIN, DE, vol. 23, no. 11, 2 July 2008 (2008-07-02), pages 1957 - 1972, XP019658955, ISSN: 1432-198X, DOI: 10.1007/S00467-008-0872-4 (B1)

CHATELET V ET AL: "Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome.", AMERICAN JOURNAL OF TRANSPLANTATION : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF TRANSPLANTATION AND THE AMERICAN SOCIETY OF TRANSPLANT SURGEONS NOV 2009, vol. 9, no. 11, November 2009 (2009-11-01), pages 2644 - 2645, XP002739219, ISSN: 1600-6143 (B1)

CHATELET VALERIE ET AL: "Efficacy of Eculizumab in a Plasmatherapy-Dependent Patient with Atypical Hemolytic Uremic Syndrome with C3 Mutation Following Plasmatherapy Withdrawal", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 112, no. 11, 16 November 2008 (2008-11-16), pages 4579, XP086679334, ISSN: 0006-4971, DOI: 10.1182/BLOOD.V112.11.4579.4579 (B1)

DAVID KAVANAGH ET AL: "Complement Regulatory Genes and Hemolytic Uremic Syndromes", ANNUAL REVIEW OF MEDICINE, vol. 59, no. 1, 1 February 2008 (2008-02-01), pages 293 - 309, XP055186136, ISSN: 0066-4219, DOI: 10.1146/annurev.med.59.060106.185110 (B1)

GILLIAN M. KEATING: "Eculizumab: A Review of Its Use in Atypical Haemolytic Uraemic Syndrome", DRUGS, vol. 73, no. 18, 1 December 2013 (2013-12-01), NZ, pages 2053 - 2066, XP055493804, ISSN: 0012-6667, DOI: 10.1007/s40265-013-0147-7 (B1)

HILLMEN P ET AL: "EFFECT OF ECULIZUMAB ON HEMOLYSIS AND TRANSFUSION REQUIREMENTS IN PATIENTS WITH PAROXYSMAL NOCTRURNAL HEMAGLOBINURIA", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 350, no. 6, 5 February 2004 (2004-02-05), pages 552 - 559, XP009057948, ISSN: 1533-4406, DOI: 10.1056/NEJMOA031688 (B1)

HILLMEN PETER ET AL: "The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 355, no. 12, 21 September 2006 (2006-09-21), pages 1233 - 1243, XP002482088, ISSN: 1533-4406, DOI: 10.1056/NEJMOA061648 (B1)

JENS N�RNBERGER ET AL: "Eculizumab for Atypical Hemolytic-Uremic Syndrome", NEW ENGLAND JOURNAL OF MEDICINE, vol. 360, no. 5, 29 January 2009 (2009-01-29), pages 542 - 544, XP055045531, ISSN: 0028-4793, DOI: 10.1056/NEJMc0808527 (B1)

RALPH A. GRUPPO ET AL: "Eculizumab for Congenital Atypical Hemolytic-Uremic Syndrome", NEW ENGLAND JOURNAL OF MEDICINE, vol. 360, no. 5, 29 January 2009 (2009-01-29), pages 544 - 546, XP055186116, ISSN: 0028-4793, DOI: 10.1056/NEJMc0809959 (B1)

REINHARD W�RZNER AND LOTHAR ZIMMERHACKL: "Therapeutic strategies for atypical and recurrent hemolytic uremic syndromes (HUS)", 1 January 2006, COMPLEMENT AND KIDNEY DISEASE,, PAGE(S) 149 - 163, XP009161632 (B1)

RICKLIN DANIEL ET AL: "Complement-targeted therapeutics", NATURE BIOTECHNOLOGY, GALE GROUP INC, US, vol. 25, no. 11, 1 November 2007 (2007-11-01), pages 1265 - 1275, XP002546813, ISSN: 1087-0156, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966895/> [retrieved on 20071107], DOI: 10.1038/NBT1342 (B1)

A. AVILA ET AL: "Remission of aHUS neurological damage with eculizumab", CLINICAL KIDNEY JOURNAL, vol. 8, no. 2, 22 January 2015 (2015-01-22), pages 232 - 236, XP055394181, ISSN: 2048-8505, DOI: 10.1093/ckj/sfu144 (B1)